3 benchmark R&D centers

Ipsen has set-up its R&D centers at the heart of three internationally reputed scientific hubs: Paris-Saclay in France, Oxford in the United Kingdom, and Cambridge in the United States. Each site is located close to leading academic research centers, cutting-edge medical centers and biotechnological companies. Interactions with key health industry players greatly increase our chances of access to innovative technologies to speed up the discovery and approval of drugs and services that improve the lives of patients.

 
The R&D center at Les Ulis is located in the Paris-Saclay hub which is home to several thousand life sciences researchers. Ipsen’s innovation teams are housed in a high-tech environment, in close contact with major scientific and academic institutions, such as Ecole Polytechnique, the French National Center for Scientific Research (CNRS), the French National Institute of Health and Medical Research (INSERM) and the Atomic Energy Commission (CEA).

One of the missions of Ipsen’s largest R&D site, established in 1969, is to accelerate clinical development and fundamental research to deepen our understanding of molecular, pharmacological, pharmacodynamic and pharmacokinetic properties of new molecules in oncology and neurology.

Following through on its open innovation strategy, Ipsen teamed up with Aepodia in a partnership signed in January 2016 covering early-stage development programs in R&D. Aepodia will provide its expertise and agility in early clinical development and in the implementation of Phase I studies up to proof of concept (POC). Aepodia and Ipsen teams will work together to optimize the design of clinical studies and their operational implementation.

> 13%

of sales invested in R&D in 2015

3

global R&D centers

~300

employees assigned to R&D

2 innovative scientific platforms

Ipsen has built two leading-edge technological platforms, toxins and peptides, fields in which we stand out for our acknowledged expertise. This specialist knowledge also opens the door to the possibility of harnessing the synergies in toxins and peptides in hybrid molecules like targeted secretion inhibitors (TSI). With their unique properties, these molecules offer potential in the treatment of neuromuscular, endocrine and proliferative disorders, as well as for pain.

Pipeline

Ipsen’s Research & Development comprises both new molecule development programs and lifecycle management programs for our existing products. During preclinical and clinical development, early identification of therapeutic targets and markers helps researchers to better define the potential value of molecules. This speeds up the process of drug development and drug approval application procedures.

Scientific affairs

Ipsen's active partnership policy underpins internal R&D, from fundamental research through to clinical development.
Last update 13/04/2017